--- title: "Content Download: Formulation screening and development packages" description: "Scalable PLA/PLGA nanoparticle packages for peptides and small molecules: formulation, QC, and release studies." --- [![White](https://resources.curapath.com/hs-fs/hubfs/White.png?width=1063&height=400&name=White.png "White")](https://curapath.com/) Resources # Content Download: Formulation Development Packages for PLA/PLGA Nanoparticles [Back to resources](https://resources.curapath.com/en/curapath-resource-library?hsLang=en) [Check other formulation packages](https://resources.curapath.com/en/curapath-formulations-development-packages-2025?hsLang=en) Form ## Fill Out The Form To Begin Your Download Curapath introduces a structured suite of **Formulation Development Packages,** designed to streamline the creation and optimization of **PLA/PLGA-based nanoparticles** for the encapsulation of **peptides** and **small molecules**. **Package Highlights:** **Essential**: Rapid development of PLA/PLGA + API nanoparticles, adapted to scalable manufacturing. **Advanced**: Enhanced targeting. **Expert**: Full analytical depth with functionalized PLGAs and in vitro studies**.** ![PLGA Nanoparticle Formulation](https://resources.curapath.com/hs-fs/hubfs/Captura%20de%20pantalla%202025-09-18%20085047.png?width=647&height=911&name=Captura%20de%20pantalla%202025-09-18%20085047.png) These packages offer increasing levels of **formulation complexity**, **analytical depth**, and **customization**, supporting scalable development from early-stage screening to preclinical readiness. Each tier includes access to proprietary methods and materials, including **shielding lipids**, **targeted PLGA variants**, and **functionalized H-terminated PLGAs**, enabling the design of high-performance, non-viral delivery systems. **Discover how our customizable, cost-effective solutions can accelerate your nanoparticle development.**   ## Resources ### [CDMO Brochure Optimize Your Formulation Processes and Fill & Finish Requests with Robust Precision Lipid and Polymer Services ](https://resources.curapath.com/en/curapath-cdmo-brochure-download?hsLang=en) ### [pSar White Paper Polysarcosine (pSar), a safer, more effective alternative to poly-ethylene glycol (PEG)](https://resources.curapath.com/en/curapath-psar-white-paper-download?hsLang=en) ### [Next generation LNPs formulation with Certest’s and Curapath’s proprietary excipients](https://resources.curapath.com/en/curapath-curapath-certest-next-generation-lnps?hsLang=en) [](https://resources.curapath.com/en/curapath-curapath-certest-next-generation-lnps?hsLang=en) Certest and Curapath have joined forces to develop a novel LNP formulation leveraging the complementary Benefits of their proprietary excipients   ### [Polymeric Nanoparticles Case Study Development of a Highly Efficient, Biodegradable, Polymeric, Non-viral Vector (NVV) Platform for Nucleic Acid Delivery](https://resources.curapath.com/en/curapath-pol-nano-case-study?hsLang=en) ### [Curapath-Knauer Application Note Development and Optimization of LNP Formulations using the NanoScaler](https://resources.curapath.com/en/curapath-knauer-app-note?hsLang=en) ### [pSar-VitE General Excipient Case Study Development of PEG-free Excipients for Drug Delivery](https://resources.curapath.com/en/vite-psar-general-excipient?hsLang=en) ### [Curapath-Knauer Services Flyer LNP Formulation and Analytical Services](https://resources.curapath.com/en/curapath-knauer-flyer-download?hsLang=en) ![Lipid-Nanopeptide_0](https://resources.curapath.com/hs-fs/hubfs/Lipid-Nanopeptide_0.png?width=500&height=500&name=Lipid-Nanopeptide_0.png) Support for Your Therapeutic Program ### Contact a Chemist Today Contact Us, and we can discuss your specific therapeutic program and how Curapath can help build the right solution to advance your unique drug. [Contact Us](https://curapath.com/?page_id=151) ![footer-Logo](https://resources.curapath.com/hubfs/footer-Logo.svg "footer-Logo") [End-to-End Services](https://curapathstg.wpenginepowered.com/end-to-end-services/) [Expertise](https://curapathstg.wpenginepowered.com/expertise/) [Non-Viral Gene Delivery](https://curapathstg.wpenginepowered.com/non-viral-gene-delivery/) [Polymer & Lipid Excipients](https://curapathstg.wpenginepowered.com/polymer-lipid-excipients/) [Analytics & Metrics](https://curapathstg.wpenginepowered.com/analytics-and-metrics/) [Products](https://20205171.hs-sites.com/en/curapath-product-catalog?hsLang=en) [Resources](https://20205171.hs-sites.com/en/curapath-resource-library?hsCtaTracking=fca93105-47df-4ecb-8060-ab8c884fed09%7C49317d58-fe6c-4c70-83cc-d920d6200f8d&hsLang=en) [About Us](https://curapath.com/about-us/) [Contact](https://curapath.com/contact-us/) [Testimonials](https://curapath.com/testimonials/) [News & Events](https://curapath.com/news-events/) [Careers](https://curapath.com/careers/) [Privacy](https://curapath.com/privacy-policy/) [Cookie Policy](https://curapath.com/cookies-policy/) [Legal Notice](https://curapath.com/legal-notice/) US Commercial Offices One Broadway, 14th Floor Cambridge, MA 02142 USA GMP Production Site & Headquarters Av. Benjamin Franklin 19 46980 Paterna, Valencia Spain Innovation & Development Site C/Alexander Graham Bell 6 46980 Paterna, Valencia Spain [![In-White-96@2x-1](https://resources.curapath.com/hs-fs/hubfs/In-White-96@2x-1.png?width=30&height=30&name=In-White-96@2x-1.png "In-White-96@2x-1")](https://www.linkedin.com/company/curapath/) Copyright © 2024 Curapath. All rights reserved.